AN2 Therapeutics Inc ANTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANTX is a good fit for your portfolio.
News
-
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
Trading Information
- Previous Close Price
- $2.28
- Day Range
- $2.20–2.37
- 52-Week Range
- $2.20–22.13
- Bid/Ask
- $2.15 / $2.39
- Market Cap
- $69.07 Mil
- Volume/Avg
- 121,380 / 503,195
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 36
- Website
- https://www.an2therapeutics.com
Comparables
Valuation
Metric
|
ANTX
|
PLRX
|
CBAY
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.55 | 1.50 | 12.65 |
Price/Sales | — | 441.50 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
ANTX
PLRX
CBAY
Financial Strength
Metric
|
ANTX
|
PLRX
|
CBAY
|
---|---|---|---|
Quick Ratio | 7.64 | 17.43 | 10.70 |
Current Ratio | 7.87 | 17.72 | 10.96 |
Interest Coverage | — | −145.34 | −5.27 |
Quick Ratio
ANTX
PLRX
CBAY
Profitability
Metric
|
ANTX
|
PLRX
|
CBAY
|
---|---|---|---|
Return on Assets (Normalized) | −48.13% | −22.68% | −30.06% |
Return on Equity (Normalized) | −53.20% | −24.50% | −51.97% |
Return on Invested Capital (Normalized) | −53.19% | −28.46% | −30.87% |
Return on Assets
ANTX
PLRX
CBAY
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kbxnjfrcby | Fdnd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nqzjtvjd | Vgvckj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zhbvhtzd | Zsclpc | $97.8 Bil | |
MRNA
| Moderna Inc | Lrqvksrp | Qrwp | $41.3 Bil | |
ARGX
| argenx SE ADR | Rsdddcc | Qwlm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xchhrjgw | Ypth | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dwnfckfzn | Hzqly | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hwpfhkvf | Lsvmrzz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Svwrptpj | Nctlnw | $12.5 Bil | |
INCY
| Incyte Corp | Lvhjqhl | Skpltd | $11.6 Bil |